May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Baseline Characteristics of a Phase 3 Clinical Study of Anecortave Acetate 15 mg in Patients With Exudative Age–Related Macular Degeneration (AMD)
Author Affiliations & Notes
  • J.S. Slakter
    Vitreous–Retina–Macula Consultants of New York, New York, NY
  • J. Jerdan
    Alcon Laboratories, Inc, Fort Worth, TX
  • F.E. Kane
    Alcon Laboratories, Inc., Fort Worth, TX
  • P. Zilliox
    Alcon Laboratories, Fort Worth, TX
  • D. Turner
    Alcon Laboratories, Inc., Fort Worth, TX
  • S.M. Robertson
    Alcon Laboratories, Inc., Fort Worth, TX
  • A. Ciardella
    Digital Angiography Reading Center, New York, NY
  • Anecortave Acetate Clinical Study Group
    Vitreous–Retina–Macula Consultants of New York, New York, NY
  • Footnotes
    Commercial Relationships  J.S. Slakter, Alcon Laboratories, Inc C, R; Novartis Ophthalmics C, R; J. Jerdan, Alcon Laboratories, Inc E; F.E. Kane, Alcon Laboratories E; P. Zilliox, Alcon Laboratories, Inc. E; D. Turner, Alcon Laboratories, Inc. E; S.M. Robertson, Alcon Laboratories, Inc. E; A. Ciardella, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1374. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.S. Slakter, J. Jerdan, F.E. Kane, P. Zilliox, D. Turner, S.M. Robertson, A. Ciardella, Anecortave Acetate Clinical Study Group; Baseline Characteristics of a Phase 3 Clinical Study of Anecortave Acetate 15 mg in Patients With Exudative Age–Related Macular Degeneration (AMD) . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1374.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To report the baseline characteristics of Study C–01–99, a phase 3 study of Anecortave Acetate 15 mg administered as a periocular posterior juxtascleral depot (PJD) or PDT with VISUDYNE® in patients with predominantly classic lesions due to exudative AMD. Methods: Patients enrolled into this study had a diagnosis of exudative AMD in their study eye with subfoveal choroidal neovascularization that was eligible for treatment with verteporfin PDT. Demographic characteristics, best corrected logMAR visual acuity (VA) and lesion characteristics by fluorescein and ICG angiography and fundus photography were assessed at baseline. Patients received treatment with Anecortave Acetate 15 mg at baseline and 6 month intervals or PDT at baseline and every 3 months if leakage was present. No prior laser or PDT treatments were permitted. Results: Of the 530 patients enrolled, 522 were eligible for the per protocol analysis. Most patients were Caucasian (97.7%) There were no significant differences between treatment groups for mean age, gender or iris color. The mean baseline logMAR VA was 0.74 (48 ETDRS letters read correctly) in the Anecortave Acetate group and 0.71 in the PDT group. Mean lesion size was 3.7 mm2 for both treatment groups and the median time from diagnosis was 37 days. There was a high incidence of small, recently diagnosed classic CNV lesions which are indicative of rapidly progressing aggressive lesions. The incidence of retinal angiomatous proliferation (RAP), subfoveal hemorrhage and fluid, and subfoveal hot spots was unusually high in this study compared to previous studies of AMD patients. Conclusions: The baseline characteristics of Study C–01–99 indicate that the lesion size was smaller and younger than previously observed in the studies of patients with predominantly classic lesions. The presence of a high incidence of characteristics such as RAP, extensive subretinal hemorrhage/fluid and subfoveal hotspots suggests that this study included unusually aggressive lesions.

Keywords: age-related macular degeneration • choroid: neovascularization • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.